News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>HSBC Research Raises INNOVENT BIO's TP to HKD110; Rating Kept Buy
In its research report, HSBC Global Research expressed optimism over the commercial outlook of INNOVENT BIO (01801.HK)'s PD1/IL2 assets and potential of its related business de...
Reset
Send
The window will close in 5 seconds
<Research>HSBC Research Raises INNOVENT BIO's TP to HKD110; Rating Kept Buy
Close
Recommend
4
Positive
6
Negative
2
 
SHORT SELL
 
STOCK INFO

In its research report, HSBC Global Research expressed optimism over the commercial outlook of INNOVENT BIO (01801.HK)  -0.750 (-0.911%)    Short selling $119.99M; Ratio 8.262%   's PD1/IL2 assets and potential of its related business development.

INNOVENT BIO boasts a strong product lineup, including innovative ADCs (antibody-drug conjugates), bispecific antibodies, and proprietary metabolic patents, which can drive sustained growth.

Related NewsCiti Raises INNOVENT BIO's TP to HKD90; New Phase Begins
HSBC Global Research raised its 2026-27 earnings forecasts by 10-58% for INNOVENT BIO. It also kept the Buy rating unchanged, with a target price sharply raised from HKD65.8 to HKD110.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-08 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.